or a pharmaceutically acceptable salt or solvate thereof, wherein:

R^1 is C_{3-6} cycloalkyl optionally substituted by one or more fluorine atoms, or C_{1-6} alkyl optionally substituted by one or more fluorine atoms, or C_{3-6} cycloalkylmethyl optionally ring-substituted by one or more fluorine atoms; and

R^2 is phenyl optionally substituted by one or more fluorine atoms.

2. (Amended) The compound of claim 1 of the formula:



IA

or a pharmaceutically acceptable salt or solvate thereof, wherein:

R^1 is either C_{3-6} cycloalkyl optionally substituted by one or more fluorine atoms, or C_{1-6} alkyl optionally substituted by one or more fluorine atoms.

3. (Amended) The compound of claim 1, wherein R^1 is either C_{4-6} cycloalkyl optionally substituted by one or two fluorine atoms, or C_{1-4} alkyl optionally substituted by from one to three fluorine atoms.

4. (Amended) The compound of claim 3, wherein R^1 is either cyclobutyl, cyclopentyl, 4,4-difluorocyclohexyl or 3,3,3-trifluoropropyl.

5. (Amended) The compound of claim 1, wherein R^2 is phenyl optionally substituted by 1 or 2 fluorine atoms.

6. (Amended) The compound of claim 5, wherein R^2 is phenyl or monofluorophenyl.

7. (Amended) The compound of claim 6, wherein R^2 is phenyl or 3-fluorophenyl.

8. (Amended) The compound of claim 1 which is selected from the group consisting of:

N-{(1S)-3-[3-(3-Isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-exo-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl}cyclobutanecarboxamide;

N-{(1S)-3-[3-(3-Isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-exo-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl}cyclopentanecarboxamide;

N-{(1S)-3-[3-(3-Isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-exo-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl}-4,4,4-trifluorobutanamide;
N-{(1S)-3-[3-(3-Isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-exo-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl}-4,4-difluorocyclohexanecarboxamide; and
N-{(1S)-3-[3-(3-Isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-exo-8-azabicyclo[3.2.1]oct-8-yl]-1-(3-fluorophenyl)propyl}-4,4-difluorocyclohexanecarboxamide;
or a pharmaceutically acceptable salt or solvate of any thereof.

9. (Amended) A pharmaceutical composition comprising a compound of claim 1 and one of a pharmaceutically acceptable excipient, a pharmaceutically acceptable diluent or a pharmaceutically acceptable carrier.

19. (Amended) A method of treating in a mammal a disorder in which the modulation of CCR5 receptors is implicated, which comprises administering to said mammal an effective amount of a compound claim 1.

20. (Amended) A method of treating HIV, a retroviral infection genetically related to HIV, AIDS, or an inflammatory disease, in a mammal, which comprises administering to said mammal an effective amount of a compound of claim 1.

21. (Amended) A method of treating, in a mammal, a respiratory disorder selected from adult respiratory distress syndrome (ARDS), bronchitis, chronic bronchitis, chronic obstructive pulmonary disease, cystic fibrosis, asthma, emphysema, rhinitis and chronic sinusitis, which comprises administering to said mammal an effective amount of a compound of claim 1.

22. (Amended) A method of treating, in a mammal, an inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, graft rejection, including a kidney or a lung allograft, endometriosis, type I diabetes, a renal disease, chronic pancreatitis, an inflammatory lung condition or chronic heart failure which comprises administering to said mammal an effective amount of a compound of claim 1.

12 ~~38~~. A compound of the formula:

T0721



(IIA).

wherein R^2 is phenyl optionally substituted by one or more fluorine atoms.

13 ~~39~~. The compound of claim ~~38~~ 12, wherein R^2 is phenyl.

14 ~~40~~. The compound of claim ~~38~~ 12 of the formula:

T0720



(II).

15 ~~41~~. The compound of claim ~~40~~ 14, wherein R^2 is phenyl.

16 ~~42~~. A compound of the formula:

T0722



(VII)

wherein R^2 is phenyl optionally substituted by one or more fluorine atoms; and P is a protecting group.

17 ~~43~~. The compound of claim ~~42~~ 16, wherein R^2 is phenyl.

18 ~~44~~. The compound of claim ~~42~~ 16, wherein P is t-butyloxycarbonyl or benzyloxycarbonyl.

19 ~~45~~. A compound of the formula:



(XII)

wherein P^1 is hydrogen or a protecting group.

46. The compound of claim 45, wherein P^1 is benzyl.

47. The compound of claim 45, or a salt thereof, having the formula:



(VIA)

48. The p-toluenesulphonate salt of the compound of claim 47.

49. A compound of the formula:



(XIV)

wherein R^1 is C_{3-6} cycloalkyl optionally substituted by one or more fluorine atoms, or C_{1-6} alkyl optionally substituted by one or more fluorine atoms, or C_{3-6} cycloalkylmethyl optionally ring-substituted by one or more fluorine atoms; and

R^2 is phenyl optionally substituted by one or more fluorine atoms.

50. The compound of claim 49, wherein R^2 is phenyl.

51. A compound of the formula:



(XVIII)

where R^2 is phenyl optionally substituted by one or more fluorine atoms.

52. The compound of claim 51, wherein R^2 is phenyl.

53. A compound of the formula:



(XIX)

wherein R^1 is C_{3-6} cycloalkyl optionally substituted by one or more fluorine atoms, or C_{1-6} alkyl optionally substituted by one or more fluorine atoms, or C_{3-6} cycloalkylmethyl optionally ring-substituted by one or more fluorine atoms; and R^2 is phenyl optionally substituted by one or more fluorine atoms.

54. The compound of claim 53, wherein R^2 is phenyl.

55. A compound selected from the group consisting of:





; and



56. A process for the preparation of a compound of claim 1 selected from a process which comprises:

(a) coupling a compound of the formula:



II

with a compound of formula:

R^1CO_2H (III);

or

(b) reaction of a compound of the formula (II) with a compound of the formula:

R^1COZ (VIB)

where Z is a carboxylic acid activating, group; or

(c) reduction of a compound of the formula:



(XIV)

;

(d) reductive amination using a compound of the formula:



(XVI)

and a compound of the formula:



(VIA)

or a salt thereof; or

(e) reductive amination using a compound of the formula:



(XV)

where Y is CN, and a compound of the formula (VIA), or a salt thereof; or

(f) alkylation of a compound of the formula (VIA), or a salt thereof, with a compound of the formula:



(XVII)

where Z^1 is a leaving group; or

(g) asymmetric reduction of a compound of the formula:



(XIX)

; or

(h) reaction of a compound of the formula (II), or a metal salt thereof, with a compound of the formula:

$R^1CO_2R^5$
(XXIV)

where R^5 is an ester forming group; or

(i) reaction of a compound of the formula:



(IIA)

either with a compound of the formula (III) under coupling conditions, or a compound of the formula (VIB), and in the presence of a a chiral catalyst:

wherein any one of processes (a) through (i) is optionally followed by conversion of a compound of claim 1 a pharmaceutically acceptable salt thereof.